译语翻译分享-中国新冠灭活疫苗获批在3到17岁人群使用

 

中国生物官方微信公号消息

China Biological Official WeChat Public Account News

经国务院联防联控机制有关部门组织论证,国药集团中国生物北京生物制品研究所的新冠病毒灭活疫苗获批在3-17岁人群中紧急使用

According to the demonstration organized by the relevant departments of the Joint Prevention and Control Mechanism of the State Council, the new coronavirus inactivated vaccine of the Beijing Institute of Biological Products of Sinopharm Group has been approved for emergency use in people aged 3-17

国药集团中国生物新冠疫苗3-17岁年龄组已经在河南完成I/II期临床试验，3-17岁人群免后中和抗体阳转率为100%，中和抗体GMT和阳转率与成人组相比无显著性差异，接种后安全性良好，不良反应主要为发热和接种部位疼痛，严重程度以1级为主，未见严重不良反应，不良反应发生率随接种剂次增加而逐渐降低

Sinopharm China Bio-New Crown Vaccine 3-17 years old age group has completed phase I/II clinical trials in Henan. After 3-17 years of age, the neutralizing antibody positive conversion rate is 100%, and the neutralizing antibody GMT and positive conversion rate is the same as that of adults There is no significant difference between the two groups. The safety after vaccination is good. The adverse reactions are mainly fever and pain at the inoculation site. The severity is mainly grade 1, and no serious adverse reactions are seen. The incidence of adverse reactions gradually decreases with the increase in the number of inoculations.

 

From website: https://my-h5news.app.xinhuanet.com/